Five things for pharma marketers to know: Thursday, December 29, 2016

Share this content:


1. Gilead Sciences, which markets the blockbuster hepatitis-C drugs Harvoni and Sovaldi, has formed a national network of employees who work with public health departments and activists to help untreated patients gain access to the drugs. (Bloomberg)

2. Tadashi Ishii, president and CEO of advertising firm Dentsu, will resign in response to the suicide of a staffer in Japan. She had been putting in 100 hours of overtime each month when she died. (NYT)

3. Boehringer Ingelheim will divest five types of animal health products so that an asset swap with Sanofi can continue. The Federal Trade Commission required the divestiture. (Reuters)

4. President-elect Trump met with a number of leading hospital CEOs, including Dr. John Noseworthy, CEO of the Mayo Clinic; Dr. David Torchiana, CEO of Partners HealthCare; and Dr. Toby Cosgrove, CEO of the Cleveland Clinic, who is reportedly being considered as the nominee for Secretary of Veterans Affairs. (Stat)

5. The FDA rejected Cempra's antibiotic treatment for community-acquired bacterial pneumonia. The regulator did not ask for further data. (Reuters)

Share this content:
Scroll down to see the next article